Pipeline
Trials
People
News
Contact
Contact
News
Button Text
August 31, 2023
AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)
August 18, 2023
AI Therapeutics Announces Investigator Initiated Phase 2 Trial at UCSF to Study LAM-001 in Patients With Bronchiolitis Obliterans Syndrome (BOS) Post-Lung Transplant
AI Therapeutics Announces Initiation of a Phase II Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)
May 9, 2023
AI Therapeutics Announces Poster Presentation at the 2023 American Thoracic Society International Conference
